WO2025133915 - COMPOUNDS WHICH BIND TO PNPLA3I148M AND THEIR USE TO TREAT LIVER DISEASES
National phase entry is expected:
Publication Number
WO/2025/133915
Publication Date
26.06.2025
International Application No.
PCT/IB2024/062773
International Filing Date
17.12.2024
Title **
[English]
COMPOUNDS WHICH BIND TO PNPLA3I148M AND THEIR USE TO TREAT LIVER DISEASES
[French]
COMPOSÉS SE LIANT À PNPLA3I148M ET LEUR UTILISATION POUR TRAITER DES MALADIES HÉPATIQUES
Applicants **
NOVARTIS AG
Inventors
BEHNKE, Dirk
BRAENDLIN, Nadine
BUSCHMANN, Nicole
FU, Xingnian
GERSPACHER, Marc
KORDIKOWSKI, Andreas
LACHAL, Julie
MAH, Robert
MARCHAND, Jean-Rémy Thierry
MEYER, Arndt
NIMSGERN, Pierre
SCHIPP, Kathrin
SUN, Yongfeng
TODOROV, Milen
Priority Data
63/611,966
19.12.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4955 | |
| EPO | Filing, Examination, Granting | 25984 | |
| Japan | Filing, Examination, Granting | 2709 | |
| South Korea | Filing, Examination, Granting | 3194 | |
| USA | Filing, Examination, Granting | 14990 |
Total:
51,832
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to compounds of Formula (I), and pharmaceutically acceptable salts and isomers of such compounds, which bind to patatin-like phospholipase domain-containing protein 3 (PNPLA3) mutation PNPLA3I148M, (I) pharmaceutical compositions comprising a compound of Formula (I), or pharmaceutically acceptable salts thereof, and their use in methods for the treatment of diseases associated with PNPLA3I148M.[French]
L'invention concerne des composés de formule (I), et des sels et isomères pharmaceutiquement acceptables de tels composés, qui se lient à la mutation de la protéine 3 contenant le domaine phospholipase de type patatine (PNPLA3) PNPLA3I148M, (I) des compositions pharmaceutiques comprenant un composé de formule (I), ou des sels pharmaceutiquement acceptables de ceux-ci, et leur utilisation dans des méthodes de traitement de maladies associées à PNPLA3I148M.